PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PerkinElmer (PKI) Tops Q3 Earnings Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 4.95% and -2.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q3 earnings. However, forex is likely to have been a dampener.
PerkinElmer (PKI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Bruker To Buy Freiberg Instruments' Magnettech EPR Business
by Zacks Equity Research
The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Why Is PerkinElmer (PKI) Down 8.4% Since Last Earnings Report?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Scientific Instruments Industry Outlook: Prospects Look Good
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is benefiting from solid prospects in emerging markets, robust end-market demand and increasing spending on health care.
PerkinElmer (PKI) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Higher revenues and growth in Diagnostics segment benefit PerkinElmer's (PKI) Q2 earnings. However, forex remains a woe.
PerkinElmer (PKI) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of -0.99% and -1.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for PerkinElmer's (PKI) Earnings in Q2?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.
PerkinElmer (PKI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold PerkinElmer (PKI) Stock for Now
by Zacks Equity Research
PerkinElmer (PKI) raises earnings per share guidance for 2019.
PerkinElmer (PKI) Down 9.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from its core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
PerkinElmer (PKI) Beats on Q1 Earnings, Hikes '19 Guidance
by Zacks Equity Research
PerkinElmer's (PKI) Q1 earnings gain from top-line growth, solid show by Diagnostics segment and strong margins. However, negative currency movement remains a headwind.
Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q1 Earnings?
by Zacks Equity Research
Strength in PerkinElmer's (PKI) core Diagnostics business is expected to drive Q1 results amid foreign exchange woes.
PerkinElmer (PKI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Varian Medical (VAR) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Varian Medical (VAR) expects to gain significantly from APAC and EMEA regions in fiscal Q2.
What's in Store for Edwards Lifesciences' (EW) Q1 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expects to gain from core Critical Care product group in Q1.
Will Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) Systems and Services revenues are likely to boost Q1 results.
3 Reasons Why Investors Should Retain PerkinElmer (PKI) Stock
by Zacks Equity Research
PerkinElmer (PKI) has been gaining investor confidence on consistently positive results.
PerkinElmer (PKI) Q4 Earnings Beat, Diagnostics Grows Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter 2018 results gain from solid segmental contributions.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cerner's (CERN) fourth-quarter 2018 results are likely to be hurt by year-over-year decline in bookings; Q4 guidance promising.
Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.